Sen. Pryor in health care reform debate
During Oct. 24 Senate floor discussion of health care reform, Majority Leader Mitchell (Maine) commended Pryor (D-Ark.) for his "action and involvement in this area" and noted Pryor's "particular interest in ...prescription drugs." Mitchell then called on Pryor to discuss pharmaceuticals, underscoring the growing recognition Pryor is getting for his interest in the subject. Mitchell said that while action on health care reform is not possible this calendar year, he intends for the Senate to vote on reform legislation during the current Congress....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth